Gene Kinney, Ph.D., is president and CEO of Prothena and has held various roles at the company since serving as its founding chief scientific officer and head of research and development. Before joining Prothena, he held positions with Elan Pharmaceuticals Inc., including senior vice president of pharmacological sciences and vice president of pharmacology. Earlier in his career, Dr. Kinney held several senior positions at Merck Research Laboratories and Bristol-Myers Squibb, and was an assistant professor at the Emory University School of Medicine.
Think for a moment about the words and phrases that life science researchers and executives use on a daily basis. I’m talking about the seemingly simple phrases like “investigational drug,” “novel... Read more »
Sponsored · Whitepaper
Virtual/hybrid trials and decentralized research can better integrate healthcare into patients’ lives and accelerate approval of new medications
PRA Health SciencesSponsored · Whitepaper
How incorporating more virtual/hybrid trials and decentralized research into clinical development can better integrate healthcare into patients’ real lives and accelerate approval of new medications.
MedpaceSponsored · Whitepaper
Acknowledging various stakeholder networks and regulatory environment variances is essential to uncover the right decision-makers in support of biologics or biosimilars
IBM Watson© 2007-2021, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.